The Philip Morris International (PM) has experienced a significant surge in share prices, leading to varied responses. While the FDA's support for ZYN's modified risk claims altered PM's investment narrative, other entities like Trek Financial LLC, Envestnet Portfolio Solutions Inc., and Strs Ohio decreased their stock positions in PM. Insider selling of US$25m of stock signals potential caution. Conversely, Mitsubishi UFJ Trust & Banking Corp, iA Global Asset Management Inc., Rakuten Investment Management Inc., and Dynasty Wealth Management LLC showed an increased stake in PM.
PM's shift toward smoke-free products - evidenced by ZYN growth and FDA approval appeal - has attracted new investor attention. However, despite strong institutional backing and considerable share price run, Jefferies downgraded PM and lowered their price target, and Wall Street Zen also downgraded PM to hold. The stock has continued to show robust smoke-free portfolio growth. PM's proposed U.S. investments, smoke-free pivot, strategic dividend reshuffling, and unflinching ambition to achieve smoke-free dominance by 2026 reflect an evolving capital strategy with high future expectations.
Philip Morris International PM News Analytics from Tue, 16 Sep 2025 07:00:00 GMT to Sat, 24 Jan 2026 22:09:14 GMT - Rating 2 - Innovation 4 - Information 8 - Rumor 1
